The ANKHD1 Knockout HEK293T Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population targeting the human ANKHD1 gene in HEK293T cells. This polyclonal population, generated through targeted gene disruption, provides a mixed pool of knockout genotypes, enabling robust loss-of-function studies without the selective pressure inherent to clonal isolation. The knockout model facilitates investigation of ANKHD1 function in a high-proliferative, widely used host cell background.
HEK293T cells are a human embryonic kidney epithelial line transformed with adenovirus 5 DNA and constitutively expressing the SV40 large T antigen. These features confer high transfectability and robust protein expression, making HEK293T the preferred host for viral production, recombinant protein generation, and a broad array of cell biology applications. The immortalized nature and well-characterized signaling landscape render this line particularly suitable for dissecting the roles of scaffold proteins in oncogenic pathways.
ANKHD1 is a multidomain scaffold protein containing ankyrin repeats and a KH domain, functioning as a critical modulator of the Hippo signaling pathway. It directly interacts with the transcriptional co-activator YAP1, as well as with TAZ, thereby influencing the transcriptional output of TEAD-family transcription factors. Downstream target genes regulated by YAP1 activity include CTGF and CYR61, which contribute to cell proliferation, migration, and extracellular matrix remodeling. The core kinase cascade??comprising MST1/2 and LATS1/2??controls YAP1 phosphorylation, and ANKHD1 scaffolds this complex to fine-tune transcriptional responses. Disruption of ANKHD1 may alter YAP1 subcellular localization and phosphorylation dynamics, thereby impacting cell cycle progression and tumor suppressor mechanisms.
In the HEK293T background, ANKHD1 knockout creates a powerful tool to examine Hippo pathway regulation in a proliferative epithelial context. These cells enable researchers to delineate how loss of ANKHD1 affects YAP1-dependent transcription independently of external matrix stiffness or density-mediated regulation, which are often confounding in primary cells. The model is particularly relevant for colorectal cancer and other cell proliferation disorders where ANKHD1 has been implicated as a tumor suppressor or oncogenic modulator.
Applications include studying ANKHD1??s role in Hippo pathway signaling using TEAD luciferase reporter assays, assessing YAP1 transcriptional activity by RT-qPCR of CTGF and CYR61, and measuring proliferation changes via BrdU or MTT assays. Co-immunoprecipitation and immunofluorescence can be employed to probe ANKHD1-YAP1 complex formation and subcellular distribution. Validation of knockout at the protein level by western blotting is recommended. This polyclonal knockout cell pool supports both mechanistic studies and high-throughput screening for pathway modulators, offering a robust, reproducible platform for cancer signaling research. For additional technical details or support, please contact Ascent Research.
